Article Dans Une Revue Scientific Reports Année : 2018

Novel Arginine-containing Macrocyclic MMP Inhibitors: Synthesis, 99mTc-labeling, and Evaluation

Résumé

Abstract Matrix metalloproteinases (MMPs) are involved in tissue remodeling. Accordingly, MMP inhibitors and related radiolabeled analogs are important tools for MMP-targeted imaging and therapy in a number of diseases. Herein, we report design, synthesis, and evaluation of a new Arginine-containing macrocyclic hydroxamate analog, RYM, its hydrazinonicotinamide conjugate, RYM1 and 99m Tc-labeled analog 99m Tc-RYM1 for molecular imaging. RYM exhibited potent inhibition against a panel of recombinant human (rh) MMPs in vitro . RYM1 was efficiently labeled with 99m TcO 4 − to give 99m Tc-RYM1 in a high radiochemical yield and high radiochemical purity. RYM1 and its decayed labeling product displayed similar inhibition potencies against rhMMP-12. Furthermore, 99m Tc-RYM1 exhibited specific binding with lung tissue from lung-specific interleukin-13 transgenic mice, in which MMP activity is increased in conjunction with tissue remodeling and inflammation. The results support further development of such new water-soluble Arginine-containing macrocyclic hydroxamate MMP inhibitors for targeted imaging and therapy.

Dates et versions

hal-04741713 , version 1 (17-10-2024)

Identifiants

Citer

Yunpeng Ye, Jakub Toczek, Kiran Gona, Hye-Yeong Kim, Jinah Han, et al.. Novel Arginine-containing Macrocyclic MMP Inhibitors: Synthesis, 99mTc-labeling, and Evaluation. Scientific Reports, 2018, 8 (1), pp.11647. ⟨10.1038/s41598-018-29941-2⟩. ⟨hal-04741713⟩
24 Consultations
0 Téléchargements

Altmetric

Partager

  • More